Serum uric acid levels and hormone therapy type: A retrospective cohort study of postmenopausal women

Jae H. Jung, Gwan Gyu Song, Young Ho Lee, Jae Hoon Kim, Myung H. Hyun, Sungjae Choi

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Objective: Serum uric acid levels increase in postmenopausal women, but decrease when hormone therapy (HT) is administered. No study has, however, evaluated the effects of different types of HT on serum uric acid levels. We therefore examined whether estrogen therapy (ET), estrogen plus progestogen therapy (EPT), and tibolone use affected serum uric acid levels in this population. Methods: We performed a retrospective cohort study of postmenopausal women. From 2005 to 2015, postmenopausal women who had undergone blood uric acid-level testing at least twice were enrolled. Participants were grouped according to HT regimen: ET, EPT, or tibolone. The nonhormone therapy group did not receive HT. Differences in serum uric acid levels were examined in each group. Our analysis was adjusted to accommodate different follow-up intervals for individual participants. Multiple variables were adjusted using the Tukey-Kramer method. Age, body mass index, hypertension, diabetes mellitus, dyslipidemia, estimated glomerular filtration rate, alcohol consumption, smoking status, and comedications were also adjusted. Results: After adjusting for multiple variables, the serum uric acid level increased to 0.87±0.27mg/dL (least squares mean±standard error) in the nonhormone therapy group, and serum uric levels in the EPT group were found to be significantly lower (-0.38±0.29mg/dL, P<0.001). The serum uric acid levels in the ET and tibolone groups did not, however, differ significantly from the nonhormone therapy group level. Conclusions: We attribute our findings to the effects of progestogen, rather than estrogen.

Original languageEnglish
Pages (from-to)77-81
Number of pages5
JournalMenopause
Volume25
Issue number1
DOIs
Publication statusPublished - 2018 Jan 1

Fingerprint

Uric Acid
tibolone
Cohort Studies
Retrospective Studies
Estrogens
Hormones
Group Psychotherapy
Progestins
Serum
Therapeutics
Dyslipidemias
Least-Squares Analysis
Glomerular Filtration Rate
Alcohol Drinking
Diabetes Mellitus
Body Mass Index
Smoking
Hypertension
Population

Keywords

  • Estrogen
  • Hormone therapy
  • Progestogen
  • Tibolone
  • Uric acid

ASJC Scopus subject areas

  • Obstetrics and Gynaecology

Cite this

Serum uric acid levels and hormone therapy type : A retrospective cohort study of postmenopausal women. / Jung, Jae H.; Song, Gwan Gyu; Lee, Young Ho; Kim, Jae Hoon; Hyun, Myung H.; Choi, Sungjae.

In: Menopause, Vol. 25, No. 1, 01.01.2018, p. 77-81.

Research output: Contribution to journalArticle

@article{198b45d6fb6c45f6b22f18f0b535c1bb,
title = "Serum uric acid levels and hormone therapy type: A retrospective cohort study of postmenopausal women",
abstract = "Objective: Serum uric acid levels increase in postmenopausal women, but decrease when hormone therapy (HT) is administered. No study has, however, evaluated the effects of different types of HT on serum uric acid levels. We therefore examined whether estrogen therapy (ET), estrogen plus progestogen therapy (EPT), and tibolone use affected serum uric acid levels in this population. Methods: We performed a retrospective cohort study of postmenopausal women. From 2005 to 2015, postmenopausal women who had undergone blood uric acid-level testing at least twice were enrolled. Participants were grouped according to HT regimen: ET, EPT, or tibolone. The nonhormone therapy group did not receive HT. Differences in serum uric acid levels were examined in each group. Our analysis was adjusted to accommodate different follow-up intervals for individual participants. Multiple variables were adjusted using the Tukey-Kramer method. Age, body mass index, hypertension, diabetes mellitus, dyslipidemia, estimated glomerular filtration rate, alcohol consumption, smoking status, and comedications were also adjusted. Results: After adjusting for multiple variables, the serum uric acid level increased to 0.87±0.27mg/dL (least squares mean±standard error) in the nonhormone therapy group, and serum uric levels in the EPT group were found to be significantly lower (-0.38±0.29mg/dL, P<0.001). The serum uric acid levels in the ET and tibolone groups did not, however, differ significantly from the nonhormone therapy group level. Conclusions: We attribute our findings to the effects of progestogen, rather than estrogen.",
keywords = "Estrogen, Hormone therapy, Progestogen, Tibolone, Uric acid",
author = "Jung, {Jae H.} and Song, {Gwan Gyu} and Lee, {Young Ho} and Kim, {Jae Hoon} and Hyun, {Myung H.} and Sungjae Choi",
year = "2018",
month = "1",
day = "1",
doi = "10.1097/GME.0000000000000953",
language = "English",
volume = "25",
pages = "77--81",
journal = "Menopause",
issn = "1072-3714",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Serum uric acid levels and hormone therapy type

T2 - A retrospective cohort study of postmenopausal women

AU - Jung, Jae H.

AU - Song, Gwan Gyu

AU - Lee, Young Ho

AU - Kim, Jae Hoon

AU - Hyun, Myung H.

AU - Choi, Sungjae

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Objective: Serum uric acid levels increase in postmenopausal women, but decrease when hormone therapy (HT) is administered. No study has, however, evaluated the effects of different types of HT on serum uric acid levels. We therefore examined whether estrogen therapy (ET), estrogen plus progestogen therapy (EPT), and tibolone use affected serum uric acid levels in this population. Methods: We performed a retrospective cohort study of postmenopausal women. From 2005 to 2015, postmenopausal women who had undergone blood uric acid-level testing at least twice were enrolled. Participants were grouped according to HT regimen: ET, EPT, or tibolone. The nonhormone therapy group did not receive HT. Differences in serum uric acid levels were examined in each group. Our analysis was adjusted to accommodate different follow-up intervals for individual participants. Multiple variables were adjusted using the Tukey-Kramer method. Age, body mass index, hypertension, diabetes mellitus, dyslipidemia, estimated glomerular filtration rate, alcohol consumption, smoking status, and comedications were also adjusted. Results: After adjusting for multiple variables, the serum uric acid level increased to 0.87±0.27mg/dL (least squares mean±standard error) in the nonhormone therapy group, and serum uric levels in the EPT group were found to be significantly lower (-0.38±0.29mg/dL, P<0.001). The serum uric acid levels in the ET and tibolone groups did not, however, differ significantly from the nonhormone therapy group level. Conclusions: We attribute our findings to the effects of progestogen, rather than estrogen.

AB - Objective: Serum uric acid levels increase in postmenopausal women, but decrease when hormone therapy (HT) is administered. No study has, however, evaluated the effects of different types of HT on serum uric acid levels. We therefore examined whether estrogen therapy (ET), estrogen plus progestogen therapy (EPT), and tibolone use affected serum uric acid levels in this population. Methods: We performed a retrospective cohort study of postmenopausal women. From 2005 to 2015, postmenopausal women who had undergone blood uric acid-level testing at least twice were enrolled. Participants were grouped according to HT regimen: ET, EPT, or tibolone. The nonhormone therapy group did not receive HT. Differences in serum uric acid levels were examined in each group. Our analysis was adjusted to accommodate different follow-up intervals for individual participants. Multiple variables were adjusted using the Tukey-Kramer method. Age, body mass index, hypertension, diabetes mellitus, dyslipidemia, estimated glomerular filtration rate, alcohol consumption, smoking status, and comedications were also adjusted. Results: After adjusting for multiple variables, the serum uric acid level increased to 0.87±0.27mg/dL (least squares mean±standard error) in the nonhormone therapy group, and serum uric levels in the EPT group were found to be significantly lower (-0.38±0.29mg/dL, P<0.001). The serum uric acid levels in the ET and tibolone groups did not, however, differ significantly from the nonhormone therapy group level. Conclusions: We attribute our findings to the effects of progestogen, rather than estrogen.

KW - Estrogen

KW - Hormone therapy

KW - Progestogen

KW - Tibolone

KW - Uric acid

UR - http://www.scopus.com/inward/record.url?scp=85039424500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85039424500&partnerID=8YFLogxK

U2 - 10.1097/GME.0000000000000953

DO - 10.1097/GME.0000000000000953

M3 - Article

C2 - 28796699

AN - SCOPUS:85039424500

VL - 25

SP - 77

EP - 81

JO - Menopause

JF - Menopause

SN - 1072-3714

IS - 1

ER -